Ignite Creation Date:
2024-05-05 @ 11:56 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00180323
Status:
COMPLETED
Last Update Posted:
2021-02-11
First Post:
2005-09-12
Brief Title:
ACC - Atrial Contribution to CRT
Sponsor:
Boston Scientific Corporation
Organization:
Boston Scientific Corporation
Study Overview
Official Title:
ACC - Atrial Contribution to CRT
Status:
COMPLETED
Status Verified Date:
2021-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This prospective study will evaluate in patients fulfilling implant criteria for Cardiac Resynchronisation Therapy CRT implant the optimal atrial contribution to the resynchronised ventricles in the event of right atrial pacing
Detailed Description:
All patients will undergo advanced echocardiographic examination pre-operative pre-discharge after implantation and at 3 and 6-months follow-up AV-delay optimization will be performed using aortic VTI measured by continuous wave Doppler in a modified 4-chamber view During optimisation aortic VTI will be measured at different heart rates reached by increasing atrial pacing 10 20 and 30 beats above intrinsic heart rate IHR
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None